Management of community-acquired pneumonia in children : South African Thoracic Society guidelines (Part 3)

dc.contributor.authorReubenson, G.
dc.contributor.authorAvenant, Theunis Johannes
dc.contributor.authorMoore, D.P.
dc.contributor.authorItzikowitz, G
dc.contributor.authorAndronikou, S.
dc.contributor.authorCohen, C.
dc.contributor.authorGreen, Robin J.
dc.contributor.authorJeena, P.
dc.contributor.authorMasekela, P.
dc.contributor.authorMasekela, R.
dc.contributor.authorNicol, M.P.
dc.contributor.authorPillay, A.
dc.contributor.authorMadhi, S.A.
dc.contributor.authorZar, Heather J.
dc.contributor.authorArgent, A.C.
dc.date.accessioned2021-09-10T14:03:37Z
dc.date.available2021-09-10T14:03:37Z
dc.date.issued2020-08
dc.description.abstractBACKGROUND. Pneumococcal conjugate vaccine (PCV) administration and other advances have been associated with a shift in the aetiological spectrum of community-acquired pneumonia, necessitating reconsideration of empiric antibiotic treatment guidelines. Management strategies have also evolved in the last decade. OBJECTIVES. To produce revised guidelines for the treatment of pneumonia in South African (SA) children, including ambulatory, hospital and intensive care management. METHODS. An expert subgroup, reviewing evidence on the management of childhood pneumonia, was convened as part of a broader group revising SA guidelines. Evidence was graded using the British Thoracic Society (BTS) grading system and recommendations were made. RESULTS. Antibiotic treatment depends on the child’s age, possible aetiology, antimicrobial resistance patterns, previous treatment, as well as factors affecting host susceptibility, including HIV, and nutritional and vaccination status. All children with signs of severe pneumonia should receive antibiotics. Children <1 month of age with pneumonia should be hospitalised and treated with ampicillin and an aminoglycoside. For treatment of ambulatory children >1 month of age, high-dose amoxicillin remains the preferred antibiotic. For severe pneumonia in this age group, hospitalisation and empiric treatment with amoxicillin-clavulanate orally is recommended; if oral therapy is not tolerated, intravenous therapy is recommended. Generally, 5 days of therapy is proposed, but longer duration may be needed in cases of severe or complicated disease. A macrolide antibiotic should be used if pertussis, mycoplasma or chlamydia pneumonia is suspected. Most hypoxic children can receive oxygen via nasal cannulae, but respiratory support should be individualised and extends to non-invasive and invasive ventilation in some cases. Children should be fed enterally; if this is not possible, administer intravenous isotonic fluids at <80% of maintenance, with monitoring of sodium levels. Empiric antibiotic treatment is the same in HIV-infected, HIV-exposed uninfected and HIV-uninfected children, although treatment for pneumocystis pneumonia and/or cytomegalovirus pneumonia should be considered in HIV-infected infants, especially in the absence of combination antiretroviral therapy. CONCLUSIONS. Updated guidelines optimise the management of childhood pneumonia in the context of changing epidemiology, improvements in HIV prevention and new evidence on management.en_ZA
dc.description.departmentPaediatrics and Child Healthen_ZA
dc.description.librarianam2021en_ZA
dc.description.sponsorshipHJZ and SAM are supported by the South African Medical Research Council.en_ZA
dc.description.sponsorshipThe South African Medical Research Councilen_ZA
dc.description.urihttp://www.samj.org.zaen_ZA
dc.identifier.citationReubenson, G., Avenant, T.J., Moore, D.P. et al. 2020, 'Management of community-acquired pneumonia in children : South African Thoracic Society guidelines (Part 3)', South African Medical Journal, vol. 110, no. 8, pp. 734-740.en_ZA
dc.identifier.issn0256-9574 (print)
dc.identifier.issn2078-5135 (online)
dc.identifier.other10.7196/SAMJ.2020.v110i8.15020
dc.identifier.urihttp://hdl.handle.net/2263/81758
dc.language.isoenen_ZA
dc.publisherHealth and Medical Publishing Groupen_ZA
dc.rights© 2020 Health & Medical Publishing Group. This work is licensed under a Creative Commons Attribution-NonCommercial Works License (CC BY-NC 3.0).en_ZA
dc.subjectPneumoniaen_ZA
dc.subjectTreatmenten_ZA
dc.subjectPaediatricsen_ZA
dc.subjectPneumococcal conjugate vaccine (PCV)en_ZA
dc.subjectCommunity-acquired pneumonia (CAP)en_ZA
dc.subjectChildrenen_ZA
dc.subjectSouth Africa (SA)en_ZA
dc.titleManagement of community-acquired pneumonia in children : South African Thoracic Society guidelines (Part 3)en_ZA
dc.typeArticleen_ZA

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Reubenson_Management_2020.pdf
Size:
192.69 KB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description: